Novo Holdings Acquires Double-Digit Stake in bioMASON

Novo Holdings Invests $72 Million in LanzaTech

August 6, 2019

Biotechnology

Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.

Novo Holdings Invests in Oxford Biomedica plc

May 28, 2019

Biotechnology

Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

Novo Holdings Acquires Majority Stake in Single Use Support

May 15, 2024

Biotechnology

Novo Holdings A/S agreed to acquire an approximately 60% controlling stake in Single Use Support, a Kufstein, Austria-based life science tools company specializing in fluid management, single-use consumables and cold-chain solutions for bioprocessing. The two founders will each retain 10% and Danaher will retain 20%; the investment is intended to support Single Use Support's next phase of global growth, particularly expansion into the US and Asia, and is subject to regulatory approvals.

Biocomposites Takes Minority Stake in Renovos Biologics

July 5, 2023

Biotechnology

Biocomposites has taken a minority equity stake in Renovos Biologics to support development and pre-market approval of the RENOVITE nanoclay therapeutic delivery platform. The investment will give Renovos access to Biocomposites' development expertise and global distribution network; Biocomposites CEO Michael Harris will join Renovos' board.

Novo Holdings Acquires BBI Group

June 15, 2021

Medical Devices

Novo Holdings A/S has agreed to acquire BBI Group from Exponent for an enterprise value of over GBP 400 million, becoming the company's majority shareholder. BBI, a Crumlin, South Wales–headquartered supplier of diagnostics reagents, lateral flow development and diagnostic manufacturing services with more than 400 employees, will benefit from Novo Holdings' life-sciences expertise to pursue organic and inorganic growth.